2019 saw a new record set for a list price of a prescription therapy—$2.1 million for the gene therapy Zolgensma® launched by AxeVis, a Novartis Company—and resulting renewed concerns over the price of treatments and whether politicos will ever be able to address the issue as the nation’s presidential election campaign season heats up.
{iframe}https://www.genengnews.com/a-lists/8-biopharma-trends-to-watch-in-2020/amp/{/iframe}